Protein is the primary macronutrient for preserving muscle mass while on GLP-1 medication
13% of the participants treated with the combined compound ended up discontinuing the trial, while 10% of the participants treated with semaglutide discontinued, however, none of the participants treated with cagrilintide discontinued their treatment plan indicating that cagrilintide was the most well tolerated by the study participants [2]
Review article: GLP-1 receptor agonists and glucagon/GIP/GLP-1 receptor dual or triple agonists-mechanism of action and emerging therapeutic landscape in MASLD
The logic behind stacking them is straightforward
Its quite challenging introduction of treatments through current NITs, especially for MASLD and MASH in diabetic and obese patients
Abumaree MH, Chamley LW, Badri M, El-Muzaini MF